Softwr

Healthcare · head to head

Lunit vs Sectra

Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite
Sectra logo

Sectra

Healthcare

Enterprise imaging and PACS from a Swedish vendor that also sells the pathology and cardiology modules on one platform

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.; Sectra sectra does not make scanners, so it cannot cross-subsidise software against modality hardware the way an integrated manufacturer can, and it often loses on headline price in a bundled tender.
  • They diverge on capability: Lunit covers Lunit INSIGHT MMG, Sectra covers Sectra IDS7.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Lunit and Sectra actually diverge.

Attributes where Lunit and Sectra differ
AttributeLunitSectra
PlatformsWebWindows, Web, Cloud, On-premise

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

Only in Sectra

  • Sectra IDS7
  • Digital pathology module
  • Sectra VNA
  • Sectra UniView
  • Image Exchange Portal
  • Sectra Amplifier
  • Breast imaging workflow
  • Sectra One Cloud

What people use each for

The jobs each tool is most often brought in to do.

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot Sectra
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot Sectra
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot Sectra
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot Sectra

Sectra

  • A hospital group digitising histopathology that does not want a second image archive and a second integration project alongside radiologynot Lunit
  • A regional health service replacing several departmental PACS with one archive and one clinician viewernot Lunit
  • An imaging provider moving off a capital refresh cycle to a cloud subscription with predictable annual costnot Lunit
  • A trust that needs to send and receive studies with neighbouring organisations routinely, where the Image Exchange Portal is already the regional normnot Lunit

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

Sectra

  • Sectra does not make scanners, so it cannot cross-subsidise software against modality hardware the way an integrated manufacturer can, and it often loses on headline price in a bundled tender.
  • Diagnostic AI is not built in house; Amplifier orchestrates third party algorithms, so the algorithms themselves need separate licences, separate clinical validation and separate information governance sign off.
  • Sectra One Cloud is priced against a committed annual study volume, and organisations whose imaging activity grows faster than forecast meet overage charges partway through the term.
  • The pathology module assumes you have already solved slide scanning and laboratory workflow, which is the larger and more expensive part of digitising histopathology and is not in Sectra scope.
  • Depth of Epic and Oracle Health integration varies by region and by which modules you buy, so a reference site in Sweden is a weak predictor of what integration will cost a United States buyer.

Pricing, plan by plan

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

Sectra

On request
  • Sectra Enterprise Imaging$undefined/year
    • Perpetual licence plus annual maintenance, or Sectra One Cloud subscription
    • Priced on committed annual study volume and modules selected
    • Pathology, cardiology and ophthalmology licensed as separate modules

Which should you pick?

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Choose Sectra if

  • You need sectra ids7.
  • You work on Windows, Web, Cloud, On-premise.
  • You also want digital pathology module.
Sectra review

Questions people ask

Is Lunit or Sectra better?
Neither clearly leads. Lunit starts at On request and Sectra at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Lunit or Sectra?
Lunit starts at On request and Sectra at On request.
Does Lunit or Sectra run on more platforms?
Lunit runs on Web. Sectra runs on Windows, Web, Cloud, On-premise.
What is Lunit best used for?
Lunit is most often used for a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated, a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically, an american breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what volpara is bought for, a tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise films. Of those, a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated and a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically are not what Sectra is typically brought in for.
What can Lunit do that Sectra cannot?
Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment. Sectra covers Sectra IDS7, Digital pathology module, Sectra VNA, Sectra UniView.

Answered from the vendors’ own pages

Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

Sectra: Does Sectra include diagnostic AI?

No. Sectra Amplifier is a marketplace and orchestration layer for third party algorithms, each licensed and validated separately.

Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

Sectra: Is pathology really on the same platform as radiology?

Yes, the pathology module uses the same archive and workflow engine, which is the main reason buyers digitising histopathology shortlist Sectra.

Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

Sectra: How is Sectra One Cloud priced?

On committed annual study volume plus the modules selected, as a subscription rather than a capital purchase. The vendor does not publish rates.

Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

Sectra: Is Sectra CE marked and FDA cleared?

The diagnostic viewing software carries CE marking under the medical device regulation and FDA 510(k) clearance for diagnostic interpretation, but the exact cleared indications differ per module and per market, so confirm for pathology specifically.

Share

Related pages

More on Lunit

More on Sectra

Keep looking

Other head to heads